Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001695
Chunk: 4

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 4
---
 Board, including, our nominees up for re-election
this year— Brent MacGregor, Scott Myers (our Chairman), Lauren Silvernail and Elaine Sun — are uniquely equipped with the
necessary expertise to continue successfully advancing Dynavax's strategy and drive long-term stockholder value. We urge you to vote "FOR" Dynavax's four director nominees on the GOLD universal proxy card today.

Deep Track’s proposed changes to the Board would install
unqualified nominees who want to effectuate an outsized capital return and shutter efforts to accelerate growth with internal and external
opportunities. This plan would destroy the future value of our business and jeopardize the long-term potential of your investment.

Our Board and management team remain focused on what matters
most – working to deliver record results and sustained growth in 2025 and beyond.

Thank you for your continued support,

The Dynavax Board of Directors

Advisors

Goldman Sachs & Co. LLC is serving as financial advisor
to Dynavax and Cooley LLP is serving as legal counsel.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing
and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial

products,
HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), which is approved in the U.S., the European
Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults
18 years of age and older, and CpG 1018 adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19
vaccines. For more information about our marketed products and development pipeline, visit .

Forward-Looking Statements

This communication contains "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements.
Forward-looking statements can generally be identified by the use of words such as "believe," "continue," "estimate,"
"expect," "will," "plan," "potential," "would" and similar expressions, or the negatives
thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding expected contributions
from our current directors, expectations regarding